The researchers reported, "The EUSTAR study revealed that a decline of over 10% in forced vital capacity (FVC) within one ...

Gossamer Bio, Inc. (Nasdaq: GOSS), a late-stage, clinical biopharmaceutical company focused on the development and ...

United Therapeutics Corp. (UTC) and Liquidia Technologies Inc. have been battling for close to a decade over their respective inhaled formulations ...

Halo Biosciences ("Halo"), a clinical-stage biotechnology company developing extracellular matrix-targeted therapies, today ...

This decision came after the full FDA approval of YUTREPIA inhalation powder for adults with pulmonary arterial hypertension ...

Yutrepia is an inhaled dry powder formulation of treprostinil approved in the U.S. to improve exercise capacity in PAH and PH ...

When the tussle is between feeding pigeons to fix your Rahu or show empathy, we often forget the hidden cost, our lungs. What ...

Alphamab Oncology (stock code: 9966.HK) announced that multiple clinical data updates for anti-HER2 biparatopic antibody-drug conjugate (ADC) JSKN003 were presented as posters at the 2025 Annual ...

Seventy-three percent of patients with breast and other solid tumors did not experience ILD recurrence when rechallenged with ...

Maharashtra sees rise in COVID-19 cases, with 873 infections and 10 deaths reported, testing and surveillance ongoing.

Shares of Liquidia Technologies Inc (NASDAQ: LQDA) were up 9.6% following the announcement that the company is scheduled to make its first commercial shipment of YUTREPIA™ (treprostinil) inhalation ...

Like other inhaled prostaglandins, YUTREPIA may cause acute bronchospasm. Patients with asthma or chronic obstructive pulmonary disease (COPD), or other bronchial hyperreactivity, are at increased ...